| Literature DB >> 34400866 |
Syed Mohammed Basheeruddin Asdaq1, Marah ALbasha2, Asmaa Almutairi2, Reham Alyabisi2, Alaa Almuhaisni2, Roaa Faqihi2, Abdulhakeem S Alamri3,4, Walaa F Alsanie3,4, Majid Alhomrani3,4.
Abstract
BACKGROUND &Entities:
Keywords: Attitude; Awareness; Behavior; Doctor; Health care professionals; Nurse; Pharmacist; Proton pump inhibitor
Year: 2021 PMID: 34400866 PMCID: PMC8347654 DOI: 10.1016/j.jsps.2021.04.033
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Knowledge level on PPI use based on demographic characteristics of the participants.
| 0.543 | |||||
| Doctor | 15 (11.6%) | 98 (76%) | 16 (12.4%) | 129 (31.2%) | |
| Pharmacist | 21 (11.5%) | 139 (76.4%) | 22 (12.1%) | 182 (44%) | |
| Nurse | 16 (15.5%) | 80 (77.7%) | 7 (6.8%) | 103 (24.9%) | |
| Overall | 52 (12.6%) | 317 (76.6%) | 45 (10.9%) | 414 (100%) | |
| 0.000 | |||||
| ≤ 25 years | 22 (33.3%) | 43 (65.2%) | 1 (1.5%) | 66 (15.9%) | |
| 26–40 years | 28 (10.6%) | 207 (78.7%) | 28 (10.6%) | 263 (63.5%) | |
| >40 years | 2 (2.4%) | 67 (78.8%) | 16 (18.8%) | 85 (20.5%) | |
| Overall | 52 (12.6%) | 317 (76.6%) | 45 (10.9%) | 414 (100%) | |
| 0.034 | |||||
| Bachelor | 45 (14.9%) | 231 (76.5%) | 26 (8.6%) | 302 (72.9%) | |
| Masters | 5 (7.4%) | 51 (75%) | 12 (17.6%) | 68 (16.4%) | |
| Ph.D or equivalent | 2 (4.5%) | 35 (79.5%) | 7 (15.9%) | 44 (10.6%) | |
| Overall | 52 (12.6%) | 317 (76.6%) | 45 (10.9%) | 414 (100%) | |
| 0.001 | |||||
| Less than 5 years | 29 (19.5%) | 115 (77.2%) | 5 (3.4%) | 149 (36%) | |
| 6–10 years | 14 (9.5%) | 111 (75.5%) | 22 (15%) | 147 (35.5%) | |
| 11–20 years | 5 (6.3%) | 63 (78.8%) | 12 (15%) | 80 (19.3%) | |
| >20 years | 4 (10.5%) | 28 (73.7%) | 6 (15.8%) | 38 (9.2%) | |
| Overall | 52 (12.6%) | 317 (76.6%) | 45 (10.9%) | 414 (100%) | |
| 0.335 | |||||
| Female | 28 (14.7% | 140 (73.3%) | 23 (12%) | 191 (46.1%) | |
| Male | 24 (10.8%) | 177 (79.4%) | 22 (9.9%) | 223 (53.9%) | |
| Overall | 52 (12.6%) | 317 (76.6%) | 45 (10.9%) | 414 (100%) | |
| 0.178 | |||||
| Tertiary | 23 (13.4%) | 123 (71.5%) | 26 (15.1%) | 172 (41.5%) | |
| Secondary | 15 (13.2%) | 90 (78.9%) | 9 (7.9%) | 114 (27.5%) | |
| Primary health care | 14 (10.9%) | 104 (81.3%) | 10 (7.8%) | 128 (30.9%) | |
| Overall | 52 (12.6%) | 317 (76.6%) | 45 (10.9%) | 414 (100%) | |
Chi-Square test.
Frequency of correct responses about PPI knowledge in different medical groups [n (%)]
| No | Question | Doctor (129) | Nurse (103) | Pharmacist (182) | Total (414) | |
|---|---|---|---|---|---|---|
| 1 | Is PPI inactive prodrug? (yes) | 83 (30%) | 70 | 126 | 279 | 0.657 |
| 2 | Do PPIs include omeprazole, pantoprazole, lansoprazole, rabeprazole, esomeprazole, etc.? (yes) | 124 | 93 | 180 | 397 | |
| 3 | Do PPI cure acid-related diseases by suppressing hydrochloric acid secretion? (yes) | 120 | 76 | 166 | 362 | |
| 4 | Can PPI be used to prevent stress ulcer? (yes) | 112 | 83 | 176 | 371 | |
| 5 | Can PPI be used to treat acute pancreatitis? (yes) | 70 | 43 | 88 | 211 | 0.166 |
| 6 | Does omeprazole have the largest individual difference compared with other PPIs? (yes) | 87 | 73 | 121 | 281 | 0.742 |
| 7 | Does omeprazole have the largest interaction compared with other PPIs? (no) | 62 | 41 | 92 | 195 | 0.211 |
| 8 | Does esomeprazole have the longest acid inhibition time compared with other PPIs? (yes) | 87 | 68 | 128 | 283 | 0.727 |
| 9 | Should omeprazole be selected for pediatric patients? (yes) | 50 | 64 | 91 | 205 | 0. |
| 10 | Should rabeprazole be selected for pregnant patients? (no) | 95 | 62 | 114 | 271 | 0.057 |
| 11 | Do you think the more expensive or newer PPI will produce better and safer effect? (no) | 44 | 30 | 71 | 145 | 0.235 |
| 12 | Is PPI usually available as enteric-coated capsules or tablets? (yes) | 86 | 52 | 121 | 259 | 0.014 |
| 13 | Should PPI usually be taken at breakfast? (yes) | 70 | 72 | 105 | 247 | 0.042 |
| 14 | Should PPI be taken after meal? (no) | 92 | 71 | 139 | 302 | 0.350 |
| 15 | Should PPI be swallowed as whole piece? (yes) | 117 | 86 | 169 | 372 | 0.039 |
| 16 | Is it advisable to increase thedose frequency rather than a single dose to improve effect? (yes) | 87 | 78 | 107 | 272 | 0.013 |
| 17 | Should patients take PPI for only 7 days in the Helicobacter pylori eradication therapy? (no) | 94 | 72 | 122 | 288 | 0.543 |
| 18 | Does PPI treatment of gastric ulcer take 2 weeks to 4 weeks? (no) | 26 | 24 | 21 | 71 | 0.022 |
| 19 | Is duration of PPI prophylaxis until no high risk factors, or able to tolerate enteral feeding? (yes) | 91 | 76 | 131 | 298 | 0.861 |
| 20 | Do you think long-term use of PPI may cause adverse reactions such as osteoporosis, pneumonia, etc.? (yes) | 102 | 52 | 145 | 299 | 0.001 |
Respondents' attitude on usage of PPI [Yes, n(%)]
| Overuse of PPI is commonly present In Saudi Arabia | 119 (92.2%) | 172 (94.5%) | 91 (88.3%) | 382 (92.3%) | 0.174 |
| The main cause of PPI overuse is doctors’ or patients’ abuse of PPI. | 119 (92.2%) | 158 (86.8%) | 89 (86.4%) | 366 (88.4%) | 0.258 |
| The main purpose of PPI overuse is Stress ulcer prophylaxis | 94 (72.9%) | 138 (75.8%) | 73 (70.9%) | 305 (73.7%) | 0.640 |
| Overuse of PPI will cause an increase in adverse drug reaction and medical cost. | 110 (85.3%) | 170 (93.4%) | 80 (77.7%) | 360 (87%) | |
| Necessary to carry out large scale education on rational use of PPI for medical staff and the public. | 113 (87.6%) | 171 (94%) | 81 (78.6%) | 365 (88.2%) | |
| Necessary to strengthen the management of community pharmacy | 112 (86.8%) | 162 (89%) | 83 (80.6%) | 357 (86.2%) | 0.136 |
| Use of PPI for short duration does not cause significant side effect | 95 (74.4%) | 144 (79.1%) | 87 (84.5%) | 327 (79%) | 0.175 |
| Over the counter dispending of PPIs should be restricted | 97 (75.2%) | 142 (78%) | 70 (68%) | 309 (74.6%) | 0.170 |
Respondents’ behavior of using PPI (always).
| Prescribe/dispense PPI when abdominal pain | 23 (17.8%) | 28 (15.4%) | 9 (8.7%) | 60 (14.5%) | 0.054 |
| Prescribe/dispense PPI when ventosity | 80 (62%) | 79 (43.4%) | 45 (43.7%) | 204 (49.3%) | 0.004 |
| Prescribe/dispense PPI when nausea | 79 (61.2%) | 88 (48.4%) | 41 (39.8%) | 208 (50.2%) | 0.023 |
| Prescribe/dispense PPI when vomiting | 64 (49.6%) | 72 (39.6%) | 34 (33%) | 170 (41.1%) | 0.067 |
| Prescribe/dispense PPI when Acid reflex | 8 (6.2%) | 8 (4.4%) | 10 (9.7%) | 26 (6.3%) | 0.175 |
| Prescribe/dispense PPI when patient has dyspepsia | 27 (20.9%) | 35 (19.2%) | 27 (26.2%) | 89 (21.5%) | 0.497 |
Average score of the knowledge, attitude and behavior on PPI use.
| Average score | ||||
|---|---|---|---|---|
| Knowledge | 13.17 ± 2.00 | 13.25 ± 1.96 | 12.48 ± 2.36 | 13.03 ± 2.10 |
| Attitude | 6.66 ± 1.37 | 6.90 ± 1.23 | 6.34 ± 1.99 | 6.69 ± 1.5 |
| Behavior | 6.58 ± 2.39 | 5.96 ± 2.37 | 5.88 ± 2.31 | 6.14 ± 2.3 |
Values are given as mean ± SD.
Factors influencing knowledge on the use of PPI.
| Factors | Beta co-efficient | P value | |
|---|---|---|---|
| Age | ≤25 years | 4.081 | 0.035 |
| 26–40 years | 2.434 | 0.072 | |
| Experience in practice | Less than 5 years | 3.942 | 0.033 |
| 6–10 years | 4.763 | 0.004 | |
| 11–20 years | 3.541 | 0.019 |
Correlation between knowledge, attitude and behavior scores.
| Knowledge | 1 | 0.165 | 0.001 | 0.082 | 0.011 | |
| Attitude | 0.165 | 0.001 | 1 | 0.151 | 0.021 | |
| Behavior | 0.082 | 0.011 | 0.151 | 0.021 | 1 | |